Cargando…
Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients
Anti-tumor necrosis factor (TNF) therapy is used to induce and maintain remission in Crohn’s disease (CD) patients. However, primary non-responders to initial treatment constitute 20–40% of cases. The causes of this phenomenon are still unknown. We aim to investigate the impact of the caspase 9 (CAS...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632275/ https://www.ncbi.nlm.nih.gov/pubmed/37658984 http://dx.doi.org/10.1007/s13353-023-00783-7 |